Ultrasensitive ctDNA-MRD Validated Following First-Line Therapy in LBCL Researchers determined detecting ctDNA-MRD with the PhasEd-Seq is a valid approach in LBCL and warrants further integration of MRD into assessments involving clinical responses.

Ultrasensitive ctDNA assays for #MRD detection show 100% specificity in predicting LBCL relapse. Phased variants outperform trackable mutations for early identification of treatment failure. From @ascopost.bsky.social.

Read the review: https://bit.ly/4t6hoEj

#lymsm #MedEd #LBCL

This paper shows that adult #LBCL with IRF4 rearrangement is biologically diverse. The authors highlight how age, tumor site, and molecular features together can refine diagnosis and support more precise risk assessment and management.

Go in depth here 👉https://bit.ly/49KYlqU

⚡️ #Allogene positionne 2026 comme une année déterminante pour le programme #CAR_T allogénique

Cema-Cel : L’essai ALPHA3 donne aux patients #LBCL une seconde chance de succès

ALLO-316 : L’essai TRAVERSE établit le potentiel CAR T dans les #TumeursSolides

ir.allogene.com/news-release...

Présentation au congrès de l' #ASH25 à #Orlando les résultats d'une étude du #LYSA réalisée à partir des données #DESCAR_T 🧬 comparant l'Axi Cel au Liso Cel pour le traitement des #LBCL 🩸 en 2e ligne.

ashpublications.org/blood/articl...

New Data on Yescarta's Efficacy in LBCL Presented at ASH 2025 Reveals Safety and Quality of Life Benefits Recent analyses presented at ASH 2025 demonstrate Yescarta's consistent safety and effectiveness for LBCL patients, including quality of life improvements.

New Data on Yescarta's Efficacy in LBCL Presented at ASH 2025 Reveals Safety and Quality of Life Benefits #United_States #Santa_Monica #Kite #Yescarta #LBCL

Allogene's CAR-T Platform Poised for Inflection Point | Adil Ali, MD posted on the topic | LinkedIn If off-the-shelf CAR-T works, the economics of oncology will be rewritten - and Allogene Therapeutics is arguably closest to that inflection point. Cema-cel is already in the pivotal Phase 2 ALPHA3 f...

Si le #CAR_T 🧬 Cema-cel ( #ALLO_501A) fonctionne, l’économie de l’oncologie sera réécrite et #Allogene 🇺🇸 est sans doute la plus proche de ce point d’inflexion.

#ASH25 #Cellectis #ALPHA3 #LBCL
www.linkedin.com/posts/adilra...

ALPHA3 - Allogene ALPHA3 NOW ENROLLING The ALPHA3 trial aims to embed an investigational allogeneic CAR T product as part of the first‑line (1L) treatment regimen in LBCL LOCATEAN ALPHA3CLINICALTRIAL SITE CEMACABTAGENE...

L’essai #ALPHA3 vise à intégrer un #CAR_T 🧬 #Allogénique 💉 d' #Allogene 🇺🇸 dans le schéma de traitement de 1ère ligne du #LBCL 🩸

Plus de 60 000 patients devraient être traités chaque année pour la LBCL et #DLBCL, aux #USA 🇺🇸, l’#UE 🇪🇺 et #UK 🇬🇧

allogene.com/alpha3/

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma PURPOSELarge B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as...

Detección del DNA tumoral circulante ultrasensible luego de la terapia del linfoma de células B grandes es más pronóstico que los criterios de respuesta radiográficos convencionales #LBCL #ctDNA ascopubs.org/doi/full/10....

Mosunetuzumab Plus Polatuzumab Vedotin Yields High CR Rate in Relapsed, Refractory LBCL Researchers determined combining mosunetuzumab with polatuzumab vedotin appears to reduce the risk of disease progression or death compared with R-GemOx in LBCL.

Among patients with transplant-ineligible R/R #LBCL, combining mosunetuzumab with polatuzumab vedotin appears to reduce the risk of disease progression or death compared with R-GemOx. Published in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/3WQSyKr

#lymphoma #lymsm

Whole Genome Sequencing Shows High Prognostic Utility in LBCL - Oncology Nurse Advisor Researchers assessed whether ULP-WGS would have prognostic utility in patients with LBCL.

Ultra-low-pass whole genome sequencing of circulating tumor DNA appears to provide important prognostic information regarding patients with #LBCL. Published in @ascopost.bsky.social JCO Precision Oncology and @hematologyadvisor.bsky.social.

https://bit.ly/4nzwSO1

#lymsm #lymphoma

Will we see you at #ASH25? Foresight will present the first real-world study of ctDNA dynamics in treated #LBCL, showcasing how #ultrasensitive MRD detection can guide personalized treatment. Excited to connect on the next stage of MRD-driven care: bit.ly/47kdmQE

Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments | OncLive Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments @clevelandclinic.bsky.social #oncology #CART #LBCL
www.onclive.com/view/real-wo...

CAR2219 CAR T-Cell Therapy Yields Responses and a Manageable Safety Profile in R/R LBCL | OncLive CAR2219 induced high response rates in relapsed/refractory LBCL, and the role of post-infusion maintenance therapy is worthy of further study.

CAR2219 CAR T-Cell Therapy Yields Responses and a Manageable Safety Profile in R/R LBCL #oncology #CART #LBCL
www.onclive.com/view/car2219...

Liso-Cel Data Confirm Durable Efficacy and Confer Broad Use in R/R LBCL | OncLive Taylor Brooks, MD, discusses data that supported the FDA approvals of liso-cel across LBCL treatment settings and details of the agent’s toxicity profile.

Liso-Cel Data Confirm Durable Efficacy and Confer Broad Use in R/R #LBCL @clevelandclinic.bsky.social #oncology

www.onclive.com/view/liso-ce...

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL | OncLive Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL @clevelandclinic.bsky.social #oncology #LBCL
www.onclive.com/view/axi-cel...

🎥 Now Available: Explore new clinical data on bispecific CAR T-cell therapies for relapsed/refractory #LBCL and #DLBCL.

👉 Watch the program and access the data: bit.ly/3ISPZUT

#Oncology #CARTCell #Lymphoma #ClinicalResearch #CME #Hematology

KITE-363 Shows Potential As a Next-Generation CAR T-Cell Therapy for R/R LBCL | OncLive Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

KITE-363 Shows Potential As a Next-Generation CAR T-Cell Therapy for R/R LBCL
#LBCL #lymsm @stanfordmedicine.bsky.social
www.onclive.com/view/kite-36...

Second-Line Axi-Cel and Liso-Cel Lead as Standards of Care in LBCL Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

Second-Line Axi-Cel and Liso-Cel Lead as Standards of Care in LBCL #hematology #LBCL
www.onclive.com/view/second-...

ADX-2191 Scores Orphan Designation in Europe for Primary LBCL of Immune-Privileged Sites The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

ADX-2191 Scores Orphan Designation in Europe for Primary LBCL of Immune-Privileged Sites #oncology #hematology #lbcl
www.onclive.com/view/adx-219...

Check out our publication in Journal of Clinical Oncology, showing Foresight CLARITY™ delivered greater prognostic accuracy than PET/CT at end of therapy in #LBCL, reinforcing the role of ultrasensitive #MRD testing for remission assessment. Read more: bit.ly/4lz93oi

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen #LBCL #lymsm #hematology
www.onclive.com/view/alpha3-...

Which therapy is offering hope for patients with high-risk #LBCL? Read our summary of a recent follow-up study of anti-CD19 CAR T-cell therapy as a first-line treatment, and stay up to date with the latest oncology management news with Medthority

#MedSky #Oncology

ow.ly/R2hh50Woceb

COALITION phase II study of glofitamab combo in high-risk LBCL COALITION phase II study of glofitamab in high-risk LBCL, results were published in Journal of Clinical Oncology.

Early-data support glofitamab combo in high-risk #LBCL

sohoinsider.com/news/early-d...

CD19/20-Targeted KITE-363 Elicits Strong Response in LBCL KITE-363 shows promising results in treating relapsed/refractory large B-cell lymphoma, with high response rates and manageable adverse events.

Saurabh Dahiya showed 87% response and 78% complete remission in hard-to-treat #LBCL with low severe side effects. Early ASCO 2025 data suggest dual CD19/CD20 CAR-T could be a powerful new option. www.cgtlive.com/view/cd19-20... #ASCO25

SCI member David Miklos & others report that allogeneic CD19 # CAR-T cells show 58% overall response and 42% complete response in CD19 CAR T-naïve patients with relapsed/refractory LBCL, with a manageable safety profile. pubmed.ncbi.nlm.nih.gov/39946666/ #LBCL"

Researchers Identify Key B-cell Lymphoma Traits Linked with Greatest Benefit from CD19 CAR T Cell Therapy - OncoDaily Researchers Identify Key B-cell Lymphoma Traits Linked with Greatest Benefit from CD19 CAR T Cell Therapy / Aixiang Jiang, Akhil Kesaraju, Ashley Wilson,

Researchers Identify Key B-cell Lymphoma Traits Linked with Greatest Benefit from CD19 CAR T Cell Therapy
@mdanderson.bsky.social

oncodaily.com/insight/b-ce...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lymphoma #LBCL #CART

Eddie Cliff: COALITION Study Compares Results of Glofitamab Combinations in LBCL - OncoDaily Eddie Cliff: COALITION Study Compares Results of Glofitamab Combinations in LBCL / Adrian Minson, cancer, Chan Y. Cheah, Eddie Cliff, Emma Verner, Jason

COALITION Study Compares Results of Glofitamab Combinations in LBCL - Eddie Cliff
@eddiecliff.bsky.social

oncodaily.com/science/coal...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #COALITION #Lymphoma #LBCL #Glofitamab

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL
#LBCL #EHA2025
www.onclive.com/view/real-wo...

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory #LBCL #EHA25 #oncology

www.onclive.com/view/jnj-449...

Lisocabtagene Maraleucel Shows Efficacy in Real-World Treatment of LBCL Researchers determined lisocabtagene maraleucel showed efficacy for patients with LBCL in a real-world setting.

Among patients with R/R large B cell #lymphoma who receive lisocabtagene maraleucel in the real-world setting, outcomes may be similar to those seen in pivotal trials leading to the drug’s approval. Published in @bloodadvances.bsky.social.

bit.ly/44BcxBU

#LBCL #lymsm